STOCK TITAN
  1. Home
  2. News
  3. LEGN

Legend Biotech Corporation American Depositary Shares - LEGN STOCK NEWS

Welcome to our dedicated page for Legend Biotech Corporation American Depositary Shares news (Ticker: LEGN), a resource for investors and traders seeking the latest updates and insights on Legend Biotech Corporation American Depositary Shares stock.

Legend Biotech Corporation (Symbol: LEGN) is an emerging clinical-stage biopharmaceutical company dedicated to the development and commercialization of cutting-edge immunotherapy technology aimed at curing cancer. The company leverages its expertise in immunology and molecular biology to advance a robust pipeline of chimeric antigen receptor (CAR) product candidates designed to address a variety of liquid and solid tumors.

Legend Biotech's primary focus is on developing CAR-T cell therapies, which have shown great promise in clinical trials. One of their flagship products, LCAR-B38M/JNJ-4528, targets multiple myeloma, a previously incurable blood cancer. Recent clinical trial results have demonstrated significant success in treating patients with refractory and relapsed multiple myeloma, showcasing the potential of their proprietary CAR-T technology.

Founded with a vision to revolutionize cancer treatment, Legend Biotech aims to safely and effectively treat previously untreatable cancers with finely-tuned CAR-T products developed through their innovative technology platform. The company's ambition has been notably fulfilled by their advances in the CARs field, as evidenced by their promising clinical outcomes.

Legend Biotech collaborates extensively with leading immunologists and molecular biologists to enhance their research and development efforts. They generate significant revenue from license and collaboration agreements, primarily from the United States.

Stay updated with the latest news and developments regarding Legend Biotech Corporation on this dedicated page.

News

Patient-Reported Outcomes from the CARTITUDE-4 Study Showed Clinically Meaningful Improvements in Health-Related Quality of Life and Reductions in Multiple Myeloma Symptoms Following Treatment with CARVYKTI® (ciltacabtagene autoleucel)

Rhea-AI Summary
Legend Biotech Corporation (NASDAQ: LEGN) announced that patient-reported outcome (PRO) data from the Phase 3 CARTITUDE-4 study showed clinically meaningful improvement in health-related quality of life following a single CARVYKTI® infusion in adults lenalidomide-refractory multiple myeloma (MM) patients. The as-treated population in CARTITUDE-4 demonstrated strong rates of progression-free survival and overall response. Longer-term data from CARTITUDE-2 showed deep and durable responses in earlier lines of treatment among patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.57%
Tags
none
-
News

Legend Biotech Reports Third Quarter 2023 Results and Recent Highlights

Rhea-AI Summary
Legend Biotech Corporation (NASDAQ: LEGN) reported unaudited financial results for the three and nine months ended September 30, 2023. The company entered into an exclusive, global license agreement with Novartis Pharma AG for potential chimeric antigen receptor T-cell (CAR-T) therapies targeting Delta-like ligand 3 (DLL3). Novartis will pay an upfront payment of $100 million and up to $1.01 billion in milestone payments. CARVYKTI® generated approximately $152 million in net trade sales during the quarter, representing a 30% increase over the previous quarter. The company also received milestone payments and appointed a new General Counsel. Legend Biotech has $1.4 billion in cash and cash equivalents, deposits, and short-term investments as of September 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.29%
Tags
earnings
-
News

Legend Biotech Announces Exclusive, Global License Agreement for Certain CAR-T Therapies Targeting DLL3

Rhea-AI Summary
Legend Biotech Corporation (NASDAQ: LEGN) has entered into an exclusive, global license agreement with Novartis Pharma AG for certain chimeric antigen receptor T-cell (CAR-T) cell therapies targeting DLL3, including its autologous CAR-T cell therapy candidate, LB2102. Legend Biotech will receive a $100M upfront payment and will be eligible to receive potential milestone payments plus tiered royalties on net sales. The deal aims to advance Legend Biotech’s autologous CAR-T cell therapy candidate, LB2102, and other potential CAR-T cell therapies targeting DLL3, using the Novartis next-generation T-Charge™ CAR-T cell therapy platform.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.33%
Tags
none
News

Legend Biotech to Host Investor Conference Call on Third-Quarter Results

Rhea-AI Summary
Legend Biotech Corporation (NASDAQ: LEGN) will host a conference call on November 20, 2023, to review third-quarter results and provide an overview of its performance for the quarter.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.91%
Tags
conferences earnings
-
News

Legend Biotech to Showcase Leadership in Multiple Myeloma Treatment at the ASH 2023 Annual Meeting

Rhea-AI Summary
Legend Biotech Corporation will present new and updated data from the CARTITUDE clinical development program for ciltacabtagene autoleucel (cilta-cel) at the 65th American Society of Hematology Annual Meeting. The presentations will include patient-reported outcomes from the Phase 3 CARTITUDE-4 study and updated efficacy and safety data from Cohorts A and B of the Phase 2 CARTITUDE-2 study. The company aims to deliver additional treatment options to patients with unmet needs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.04%
Tags
none
-
News

Legend Biotech Reports Second Quarter 2023 Results and Recent Highlights

Rhea-AI Summary
Legend Biotech Corporation (NASDAQ: LEGN) submitted sBLA and Type II Variation Application for CARVYKTI® to FDA and EMA, seeking approval for earlier treatment of patients with relapsed or refractory multiple myeloma. New data from clinical studies were presented at ASCO and EHA. Financial results for the three and six months ended June 30, 2023, reported $1.5 billion in cash and cash equivalents, time deposits, and short-term investments. Legend Biotech received milestone payments and completed financings in 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.83%
Tags
earnings
News

Legend Biotech to Host Investor Conference Call on Second-Quarter Results

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.65%
Tags
conferences earnings
-
News

Legend Biotech Announces Submission of Supplemental Application to the U.S. FDA for Expanded Use of CARVYKTI® (ciltacabtagene autoleucel)

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.21%
Tags
none
-
News

Ciltacabtagene Autoleucel (cilta-cel) Reduced Risk of Disease Progression or Death by 74% vs Standard Regimens for Adult Patients with Relapsed and Refractory Multiple Myeloma in CARTITUDE-4 Study

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.06%
Tags
none
News

Legend Biotech Announces Participation in Upcoming Investor Conferences

Rhea-AI Summary
Legend Biotech (NASDAQ: LEGN) will participate in upcoming investor conferences: Jefferies Healthcare Conference on June 7, 2023, and Goldman Sachs 44th Annual Global Healthcare Conference on June 14, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.06%
Tags
conferences

FAQ

What is the current stock price of Legend Biotech Corporation American Depositary Shares (LEGN)?

The current stock price of Legend Biotech Corporation American Depositary Shares (LEGN) is $32.8 as of December 24, 2024.

What is the market cap of Legend Biotech Corporation American Depositary Shares (LEGN)?

The market cap of Legend Biotech Corporation American Depositary Shares (LEGN) is approximately 6.0B.

What is Legend Biotech Corporation's main focus?

Legend Biotech focuses on developing and commercializing immunotherapy technology to treat various types of cancer.

What is CAR-T therapy?

CAR-T therapy involves modifying T cells to express chimeric antigen receptors that can target and destroy cancer cells.

What is Legend Biotech's lead product candidate?

Their lead product candidate is LCAR-B38M/JNJ-4528, a CAR-T cell therapy for treating multiple myeloma.

What types of cancer does Legend Biotech target?

Legend Biotech targets a wide range of liquid and solid tumors, with a significant focus on multiple myeloma.

Where does Legend Biotech generate most of its revenue?

The majority of Legend Biotech's revenue comes from the United States through license and collaboration agreements.

How successful have Legend Biotech's clinical trials been?

Their clinical trials have shown promising results, particularly in treating patients with refractory and relapsed multiple myeloma.

Who are Legend Biotech's collaborators?

Legend Biotech collaborates with leading immunologists and molecular biologists to advance their research and development.

What is the vision behind Legend Biotech's founding?

The company was founded on the vision of safely and effectively treating previously incurable cancers with innovative technology.

What is unique about Legend Biotech's technology platform?

Their platform focuses on developing finely-tuned CAR-T products, which have demonstrated significant clinical success.

How can I stay updated on Legend Biotech's latest news?

You can stay updated by following the latest news and developments on their dedicated page on StockTitan.

Stock LEGN logo
Legend Biotech Corporation American Depositary Shares

Nasdaq:LEGN

LEGN Rankings

#1162 Ranked by Market Cap
N/A Ranked by Dividends

LEGN Stock Data

6.02B
181.05M
1.31%
51.22%
12.49%
Biotechnology
Healthcare
Link
United States of America
Somerset